Metabolic abnormalities increase the risk of stroke, and reduce recanalization rates and increase the risk of hemorrhage, making tissue-type plasminogen activator (tPA) treatment potentially hazardous for stroke patients with diabetes mellitus or poststroke hyperglycemia (Jiang et al., 2020; Zhou et al., 2020). The gene discussed is PLAT; the disease is Stroke.